Skip to Content
Merck
  • The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.

The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.

Neurobiology of disease (2016-10-19)
Richard P Hulse, Robert A R Drake, David O Bates, Lucy F Donaldson
ABSTRACT

Neuropathic pain results from neuroplasticity in nociceptive neuronal networks. Here we demonstrate that control of alternative pre-mRNA splicing, through the splice factor serine-arginine splice factor 1 (SRSF1), is integral to the processing of nociceptive information in the spinal cord. Neuropathic pain develops following a partial saphenous nerve ligation injury, at which time SRSF1 is activated in damaged myelinated primary afferent neurons, with minimal found in small diameter (IB

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Neurofilament 200 (Phos. and Non-Phos.) antibody produced in mouse, clone N52, ascites fluid
Sigma-Aldrich
SRPIN340, ≥98% (HPLC)